Manufacturing / Pharmaceutical Preparations
Aprea Therapeutics, Inc.
APRE
$0.59
+$0.03 (+5.20%)
Price as of Oct 9, 2026 20:41 UTC
10 M
Market Cap (Micro Cap)
Nov 10
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $0.72
- Above 50-day average $0.74
- Above 200-day average $0.85 · -28.6%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 2d ago
Volume
- Below-average volume 1.0x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for APRE options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
14 buys
0 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | BIZZARI JEAN-PIERRE | Grant | 3,135 | $0 | -23.3% | |
| Jun 16, 2026 | BIZZARI JEAN-PIERRE | Grant | 12,555 | $0 | -23.3% | |
| Jun 16, 2026 | HENNEMAN JOHN B III | Grant | 12,555 | $0 | -23.3% | |
| Jun 16, 2026 | HENNEMAN JOHN B III | Grant | 3,135 | $0 | -23.3% | |
| Mar 31, 2026 | Peters Richard | Other | 123,915 | $0 | -26.3% | |
| Mar 31, 2026 | Peters Richard | Other | 123,915 | $99,999 | -30.6% | |
| Mar 31, 2026 | Peters Richard | Buy | 123,915 | $99,999 | -30.6% | |
| Mar 31, 2026 | Hamill John P. | Other | 30,978 | $0 | -26.3% | |
| Mar 31, 2026 | Hamill John P. | Buy | 30,978 | $0 | -26.3% | |
| Mar 31, 2026 | Hamill John P. | Buy | 30,978 | $24,999 | -30.6% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 10, 2026 | Q2 2026 | -$0.24 | |||
| Mar 31, 2026 | Q1 2026 | -$0.23 | -$0.22 | +6.2% | Beat |
| Dec 31, 2025 | Q4 2025 | -$0.40 | -$0.32 | +19.6% | Beat |
| Sep 30, 2025 | Q3 2025 | -$0.35 | -$0.47 | -36.1% | Miss |
| Jun 30, 2025 | Q2 2025 | -$0.76 | -$0.53 | +30.3% | Beat |
| Dec 31, 2024 | Q4 2024 | -$0.70 | -$0.49 | +30.0% | Beat |
Track APRE with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for APRE and your entire portfolio.